All News

Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.

Cemiplimab-rwlc (Libtayo) is the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the United States.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Get involved this October and show your appreciation for the work pharmacists do.

Dacomitinib tablets (Vizimpro, Pfizer) received FDA approval for the first-line treatment of patients with metastatic non-small cell lung cancer.

The FDA has approved Eli Lilly’s preventive migraine treatment galcanezumab-gnlm (Emgality).

Pregnant women take herbal and natural products (HNPs) as alternatives to prescription medications, but, HNPs have active ingredients and drug interactions that can potentially cause harm to both the mother and her baby.

Dacomitinib (Vizimpro, Pfizer) is indicated for patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Galcanezumab-gnlm (Emgality), a once monthly, self-administered 120-mg subcutaneous injection, is indicated for the preventive treatment of migraine in adults.

Top news of the week from Specialty Pharmacy Times.

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

A Mississippi nurse practioner and former family clinic owner was sentenced to 42 months in prison and ordered to pay more than $1 million in restitution for her role in a health care benefits fraud scheme.

A generic version of Cialis® (tadalafil, Eli Lilly) tablets (2.5 mg, 5 mg, 10 mg, 20 mg) for the United States market has been annouced by Teva Pharmaceuticals

A combination regimen of a CTLA4 targeted therapy and a PD-1 targeted therapy could be beneficial in treating ovarian cancer.

A new report published in JAMA Oncology highlights the cost burden of utilizing prostate cancer screening and treatment in this age group.

Inconsistency of insurance policy coverage, unaffordability, and difficulty accessing vaccine providers were found to be key barriers for adult immunization.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A federal bill that would lift ‘gag clauses’ prohibiting pharmacists from sharing prescription drug prices with customers was unanimously passed by the House of Representatives Tuesday.

Several hurdles remain for biosimilars to flourish in the US market.

National Penicillin Allergy Day highlights negative impact of Inaccurate allergy diagnoses.

How the re-emergence of social media tribes has shifted patient expectations of specialty pharmacy communication

Unprecedented in scale, the AMR Challenge charges pharmaceutical and health insurance companies, food animal producers and purchasers, medical professionals, government health officials, and other industry leaders from around the world to work together to address antibiotic resistance.

Majority of older patients with cancer and those who survived the disease found to have high levels of social and psychological wellbeing.

A pair of new studies is shedding light on a rare, but scientifically important, group of people with HIV who are able to maintain viral control even after stopping antiretroviral therapy.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.